Maharashtra FDA seeks price curbs after finding 2,841% markups on hospital consumables
Maharashtra FDA has asked the Department of Pharmaceuticals and NPPA to review pricing of IV sets, catheters, syringes and other hospital consumables. The move follows findings that an IV infusion set procured for ₹11.05 was sold at an MRP of ₹325.
What happened
Maharashtra Food and Drugs Administration · Maharashtra FDA has asked the Department of Pharmaceuticals and NPPA to review hospital-consumable pricing after
Key facts
- 2,841% maximum reported markup
- ₹11.05 IV infusion-set procurement price
- ₹325 IV infusion-set MRP
- ₹29.41 catheter procurement price
- ₹310 catheter MRP
What changed
Maharashtra FDA has asked the Department of Pharmaceuticals and NPPA to review hospital-consumable pricing after finding markups up to 2,841%. The regulator seeks trade-margin caps, price monitoring and guidelines for IV sets, syringes, catheters and other medical devices.
Why this matters
Prepare for tighter price scrutiny on hospital consumables, with margin caps and procurement reforms likely to pressure distributor, hospital and healthcare-retail economics.
What to watch
- Formal NPPA or Department of Pharmaceuticals consultation, committee formation or data request covering hospital consumables.
- Inclusion of additional consumables under price-monitoring, trade-margin rationalisation or the National List of Essential Medicines framework.
- Maharashtra FDA notices, hospital billing audits, penalties or mandatory disclosure rules for consumables used in procedures.
- Large hospital chains announcing standardised consumable pricing, all-inclusive procedure packages or procurement-cost-linked billing.
- Manufacturer list-price cuts, distributor commission restructuring, and acceleration of group-purchasing or centralised hospital tenders.